Table 2.
Indicator (mean) | EE
|
WE
|
||||
---|---|---|---|---|---|---|
Reported | Actual | P-value | Reported | Actual | P-value | |
Routine DST | 0.88 (0.72–1.04) | 0.34 (0.31–0.37) | 0.03 | 0.94 (0.82–1.06) | 0.62 (0.55–0.68) | 0.18 |
RHZE initiated | 1.75 (1.43–2.07) | 0.99 (0.92–1.08) | 0.03 | 2.00 (−) | 1.52 (1.40–1.63) | NA |
cART ≤ 2 months | 1.00 (0.51–1.49) | 0.90 (0.82–0.96) | 0.78 | 1.00 (0.57–1.55) | 1.43 (1.31–1.55) | 0.27 |
Total score | 3.63 (3.08–4.18) | 2.23 (2.12–2.34) | 0.002 | 4.00 (3.47–4.53) | 3.56 (3.37–3.75) | 0.28 |
n = 33 treatment centres (16 in EE and 17 in WE).
Figures represent mean HCI score per centre (reported) and per patient (actual) with 95% confidence interval (CI). Please note that for the WE reported RHZE score it was not possible to calculate a 95% CI as every centre answered positively.
Maximum HCI scores per indicator: routine DST: 1; RHZE: 2; cART ≤ 2 months: 2.
cART, combination antiretroviral therapy; DST, drug susceptibility testing; NA, not applicable; RZHE, rifampicin, isoniazid, pyrazinamide and ethambutol.